Literature DB >> 4758423

Pharmacodynamics of practolol in chronic renal failure.

J B Eastwood, J R Curtis, R B Smith.   

Abstract

Plasma levels of practolol were measured in advanced chronic renal failure. The plasma half life was found to be markedly prolonged. During haemodialysis considerable shortening of the half life occurred. Therapeutic blood levels of practolol can be achieved in maintenance haemodialysis patients by the administration of 200 mg of the drug by mouth at the beginning and end of each dialysis.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4758423      PMCID： PMC1587452          DOI： 10.1136/bmj.4.5888.320

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  4 in total

1.  The metabolism and distribution of the selective adrenergic beta blocking agent, practolol.

Authors:  B Scales; M B Cosgrove
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

2.  A comparison of the effect on airway resistance of a new beta blocking drug, ICI.50,172 and propranolol.

Authors:  A G Macdonald; R S McNeill
Journal:  Br J Anaesth       Date:  1968-07       Impact factor: 9.166

3.  Effect of a new adrenergic beta-blocking agent (ICI 50,172) on heart rate in relation to its blood levels.

Authors:  J D Fitzgerald; B Scales
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1968

4.  Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA.

Authors:  C Chantler; E S Garnett; V Parsons; N Veall
Journal:  Clin Sci       Date:  1969-08       Impact factor: 6.124
  4 in total
  9 in total

1.  Clinical pharmacokinetics of beta-adrenoreceptors blockers.

Authors:  G Johnsson; C G Regårdh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 2.  Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents.

Authors:  W H Frishman; E J Lazar; G Gorodokin
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  The kidney and antihypertensive therapy.

Authors:  R R Bailey
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

Authors:  B Flouvat; S Decourt; P Aubert; L Potaux; M Domart; A Goupil; A Baglin
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

8.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

9.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.